Renaissance Technologies
ABOS icon

Renaissance Technologies’s Acumen Pharmaceuticals ABOS Stock Holding History

Renaissance Technologies’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
675,025
+201,079
+42% +$497K ﹤0.01% 2017
2026
Q1 		$1.12M Buy
473,946
+50,846
+12% +$130K ﹤0.01% 2214
2025
Q4 		$893K Sell
423,100
-161,192
-28% -$320K ﹤0.01% 2345
2025
Q3 		$999K Buy
584,292
+337,704
+137% +$467K ﹤0.01% 2479
2025
Q2 		$286K Sell
246,588
-10,112
-4% -$10.9K ﹤0.01% 3060
2025
Q1 		$282K Sell
256,700
-513
-0.2% -$733 ﹤0.01% 2943
2024
Q4 		$442K Sell
257,213
-48,887
-16% -$118K ﹤0.01% 2899
2024
Q3 		$759K Sell
306,100
-32,000
-9% -$86.8K ﹤0.01% 2597
2024
Q2 		$818K Buy
+338,100
New +$1.08M ﹤0.01% 2437
2023
Q4 		– Sell
-87,400
Closed -$363K – 3686
2023
Q3 		$363K Buy
87,400
+42,600
+95% +$263K ﹤0.01% 2852
2023
Q2 		$215K Buy
44,800
+7,355
+20% +$35.2K ﹤0.01% 3273
2023
Q1 		$152K Buy
37,445
+5,145
+16% +$26.9K ﹤0.01% 3368
2022
Q4 		$174K Buy
+32,300
New +$217K ﹤0.01% 3469
2022
Q1 		– Sell
-21,609
Closed -$146K – 4035
2021
Q4 		$146K Buy
+21,609
New +$238K ﹤0.01% 3612

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Renaissance Technologies's ABOS Position: Q2 2026 in Review

Renaissance Technologies increased its Acumen Pharmaceuticals (ABOS) stake by 42% in Q2 2026, buying an estimated $497K and bringing the position to 675,025 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Renaissance Technologies first reported a position in ABOS in Q4 2021 and has held it in 14 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Renaissance Technologies held 675,025 shares of Acumen Pharmaceuticals worth $1.8M as of Q2 2026.
  • Renaissance Technologies bought 201,079 Acumen Pharmaceuticals shares in Q2 2026, an estimated $497K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2017 holding.
  • Renaissance Technologies first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.